Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

Completed · Phase 3 · Has a placebo group

Conditions studied: Moderate to Very Severe Chronic Obstructive Pulmonary Disease

In brief

The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies

Key facts

Study ID
NCT02138916
Run by
AstraZeneca
People needed
1656
Starts
2014-06-13
Expected to finish
2018-04-10
Last updated by the study team
2019-06-13

Who can join

Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.